Key Points
- Insider sales: Brian Daniel Webster sold 15,000 KMTS shares on Jan 15 at $22.80 for $342,000 and had sold another 15,000 on Dec 29 at $26.59 for $398,850, leaving him with 394,786 shares after the Jan 15 trade (the Jan 15 sale reduced his stake by 3.66%).
- Stock snapshot: KMTS has a $1.34 billion market cap, a negative P/E (-7.26), 50-day/200-day SMAs of $25.54/$22.22, and a 1-year trading range of $13.25–$30.00 (shares opened at $23.00 on Wednesday).
- Analyst consensus: Six analysts rate KMTS a Buy, one a Hold and one a Sell, with a MarketBeat consensus of "Moderate Buy" and a $29.00 average price target, though opinions vary across firms.
Kestra Medical Technologies, Ltd. (NASDAQ:KMTS - Get Free Report) insider Brian Daniel Webster sold 15,000 shares of the business's stock in a transaction dated Thursday, January 15th. The shares were sold at an average price of $22.80, for a total transaction of $342,000.00. Following the completion of the sale, the insider owned 394,786 shares in the company, valued at approximately $9,001,120.80. This trade represents a 3.66% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink.
Brian Daniel Webster also recently made the following trade(s):
- On Monday, December 29th, Brian Daniel Webster sold 15,000 shares of Kestra Medical Technologies stock. The stock was sold at an average price of $26.59, for a total transaction of $398,850.00.
Kestra Medical Technologies Price Performance
Shares of KMTS opened at $23.00 on Wednesday. The firm has a 50-day simple moving average of $25.54 and a two-hundred day simple moving average of $22.22. The stock has a market cap of $1.34 billion and a PE ratio of -7.26. Kestra Medical Technologies, Ltd. has a 1-year low of $13.25 and a 1-year high of $30.00. The company has a debt-to-equity ratio of 0.26, a current ratio of 5.47 and a quick ratio of 5.47.
Hedge Funds Weigh In On Kestra Medical Technologies
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. China Universal Asset Management Co. Ltd. purchased a new position in Kestra Medical Technologies in the third quarter valued at approximately $48,000. BNP Paribas Financial Markets grew its position in shares of Kestra Medical Technologies by 148.9% in the 3rd quarter. BNP Paribas Financial Markets now owns 2,738 shares of the company's stock valued at $65,000 after buying an additional 1,638 shares during the last quarter. Brown Brothers Harriman & Co. raised its stake in Kestra Medical Technologies by 26.8% during the 3rd quarter. Brown Brothers Harriman & Co. now owns 3,104 shares of the company's stock worth $74,000 after acquiring an additional 656 shares in the last quarter. Police & Firemen s Retirement System of New Jersey purchased a new stake in Kestra Medical Technologies in the second quarter valued at $54,000. Finally, New York State Common Retirement Fund acquired a new position in Kestra Medical Technologies in the second quarter valued at $93,000.
Wall Street Analyst Weigh In
KMTS has been the subject of several research analyst reports. Wells Fargo & Company raised their price target on Kestra Medical Technologies from $27.00 to $28.00 and gave the stock an "overweight" rating in a research report on Friday, December 12th. BTIG Research started coverage on Kestra Medical Technologies in a research note on Tuesday, November 18th. They set a "buy" rating and a $32.00 target price on the stock. The Goldman Sachs Group set a $24.00 target price on Kestra Medical Technologies in a report on Friday. Piper Sandler boosted their price target on shares of Kestra Medical Technologies from $27.00 to $30.00 and gave the stock an "overweight" rating in a research note on Friday, December 12th. Finally, Weiss Ratings reissued a "sell (d-)" rating on shares of Kestra Medical Technologies in a research note on Wednesday, December 24th. Six research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $29.00.
View Our Latest Stock Report on Kestra Medical Technologies
About Kestra Medical Technologies
(
Get Free Report)
We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of our Cardiac Recovery System platform is the ASSURE WCD, a next generation wearable cardioverter defibrillator (“WCD”) used to protect patients at an elevated risk of sudden cardiac arrest (“SCA”), a major public health problem that accounts for approximately 50% of all cardiovascular deaths in the U.S.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
